^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BBT-176

i
Other names: BBT-176
Company:
Bridge Biotherap
Drug class:
EGFR inhibitor, Tyrosine kinase inhibitor
Related drugs:
8ms
Journal
|
EGFR (Epidermal growth factor receptor)
|
Tagrisso (osimertinib) • BBT-176
12ms
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment (clinicaltrials.gov)
P1/2, N=45, Terminated, Bridge Biotherapeutics, Inc. | Trial completion date: Jun 2024 --> Nov 2023 | Active, not recruiting --> Terminated; Sponsor's decision considering the changing treatment landscape for NSCLC
Trial completion date • Trial termination
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
|
BBT-176
1year
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. (PubMed, Clin Cancer Res)
BBT-176 is a fourth-generation EGFR inhibitor showing promising preclinical activity against NSCLC resistant to current EGFR TKIs.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR C797S
|
Erbitux (cetuximab) • Tagrisso (osimertinib) • BBT-176
2years
Enrollment change • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
|
BBT-176
over2years
Identification of next-generation EGFR degraders to treat non-small cell lung cancer (NSCLC) patients (AACR 2022)
A PK study of C-4383 in rats showed good exposure with moderate CL when administered intravenously (CL = 8.51 mL/min/kg, AUC = 5911 ng•h/mL).In summary, we identified heterobifunctional degraders using a 4th generation EGFR inhibitor, BBT-176, that are active in EGFR mutant NSCLC cells harboring single or C797S-containing multiple mutations. We are currently making our efforts on the improvement of physicochemical properties of EGFR mutant targeted heterobifunctional compounds.
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR wild-type • EGFR C797S • EGFR H1975
|
BBT-176
over3years
Clinical • New P1/2 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
|
Erbitux (cetuximab) • BBT-176